Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 13/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | BRD1 | O95696 | 1/20 | 0.41 |
| ▸ | TAF1 | P21675 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.41 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.41 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16259909 | 0.84 | BRD9 (0.68) | BRD9BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL15711581 | 0.81 | BRD4 (0.49) | BRD9BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL14246825 | 0.78 | L3MBTL1 (0.41) | BRD9BRD4RXFP1L3MBTL1TDP1 | |
| SCHEMBL15711583 | 0.77 | BRD4 (0.49) | BRD9BRD4KAT2BRXFP1L3MBTL1 | |
| SCHEMBL20160275 | 0.77 | RXFP1 (0.40) | BRD9BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL6620694 | 0.74 | RXFP1 (0.42) | BRD9BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL20160027 | 0.74 | L3MBTL1 (0.40) | BRD9BRD4CREBBPCECR2BRD2 | |
| SCHEMBL16259900 | 0.74 | ALDH1A1 (0.46) | BRD9BRPF1BRD4CREBBPCECR2 | |
| SCHEMBL16244397 | 0.74 | RXFP1 (0.37) | BRD9BRD4CREBBPCECR2KAT2B | |
| SCHEMBL31201620 | 0.73 | BRD4 (0.49) | BRD9BRD4KAT2BRXFP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004110-B1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| EP-3004110-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| WO-2014191896-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | PKD1, PKD2, REN | BRD9 996/4885BRPF1 1675/4885BRD4 609/4885 |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | PKD1, PKD2, REN | BRD9 1003/4885BRPF1 1662/4885BRD4 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.